September 17, 2014 – Source: Integra

PLAINSBORO, N.J., Sept. 17, 2014 (GLOBE NEWSWIRE) — Integra LifeSciences Holdings Corporation (Nasdaq:IART) and Medtronic, Inc. today announced an agreement in which Integra will acquire Medtronic’s MicroFrance and Xomed manual ENT and laparoscopy instrumentation lines for approximately $60 million in cash. Integra expects the transaction to close, subject to customary closing requirements, in the fourth quarter of 2014.

The MicroFrance business, which includes Xomed’s manual ENT instruments, designs, manufactures and sells reusable handheld instruments to ear, nose and throat (“ENT”) and laparoscopy surgical specialists. Under the terms of the agreement, Integra will acquire a portfolio of approximately 4,000 MicroFrance and Xomed manual ENT and laparoscopic surgical instruments, as well as the St. Aubin le Monial, France manufacturing facility. Integra plans to fund this transaction with cash held outside the U.S.

“This announcement reflects Integra’s continuing commitment to building our Instruments business. The transaction provides access to R&D, service & repair and other infrastructure already in place in St. Aubin le Monial, France, which will improve our ability to service our current portfolio and to develop new products,” said Debbie Leonetti, Integra’s CVP, President, U.S. Instruments. “These products also align nicely with our current sales channels as well as adjacent divisions, particularly our Neurosurgery business.”

The addition of the MicroFrance business will expand Integra’s Instruments presence outside the US. In the most recent annual reporting period, sales from the products being acquired totaled approximately $30 million, two-thirds of which were generated outside the U.S.

“We are excited about adding the MicroFrance business, which advances our strategic objectives in both our Instruments and International businesses while meeting our profitability and return goals,” said Glenn Coleman, Integra’s Chief Financial Officer.

Integra expects to record approximately $27 million to $30 million in revenue and approximately 10 cents of adjusted EPS in calendar 2015 from this acquisition. The earnings accretion should rise after the first year once certain sales transitions are complete. The Company expects the acquisition to contribute less than $5 million in revenue and be neutral to earnings in the fourth quarter of 2014. The transition and integration is expected to be completed by the second half of 2015.

About Integra

Integra LifeSciences, a world leader in medical technology, is dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care. Integra offers innovative solutions in orthopedic extremity surgery, neurosurgery, spine surgery, and reconstructive and general surgery. For more information, please visit www.integralife.com

CONTACT: Integra LifeSciences Holdings Corporation

         Investors:
         Angela Steinway
         (609) 936-2268
         angela.steinway@integralife.com

         Media:
         Gianna Sabella
         (609) 936-2389
         gianna.sabella@integralife.com

French BioBeach has welcomed a regional economic mission from the PACA region (South-East of France) in San Diego, California, on the occasion of the “2014 BIO International Convention”, that took place from June 23 to 26. The objective was to promote the Biotech sector from Provence-Alpes-Côte d’Azur and concretize an action program initiated 2 years towards the United States, especially with California and San Diego, considered as a territory of excellence for Biotechnologies.

Led by Patrick Allemand, 1st Vice President of the Region and President of the new Regional Agency for Innovation and Internationalization of Companies (ARII), Dominique Esteve, President of the Regional  Chamber of Commerce and Industry (CCIR) and Jacquie Berthe, Chairman of the Competitiveness Cluster Eurobiomed, this mission involved all regional economic actors involved for several years in trade with San Diego, and gathered under the “South Bio Alliance” label: the economic development agencies Provence Promotion and Team Côte d’Azur, the competitiveness cluster / PRIDES Mediterranean Sea (Pole Mer), the Southeast Technologies Transfer Accelerator Society (SATT South East), as well as companies from Provence-Alpes-Côte d’Azur (Txcell, Syncrosome, Trophos, Iris Pharma, Nicox, Provepharm , Neuroservice and Medicodose Systems) and Languedoc Roussillon (Medincell, Ciloa and Régimbeau Law Office). The objective was to implement real and lasting partnership and economic development actions between the Provence-Alpes-Côte d’Azur Region and San Diego. Beyond the Biotechnology industry, it was also the occasion to identify opportunities for economic exchanges in other sectors, and the terms of partnership.

The program of the delegation was as follows:

Monday, June 23^rd:

• Visit of Janssen Labs, a La Jolla-based Life Science innovation center
• Fast-Track R&D Partnering with France, a satellite event of the BIO Convention co-organized by French BioBeach, intended to discover the expertise and innovation developed by French biotech companies
• Meeting with San Diego Mayor, M. Kevin Faulconer
• Meeting with the Port of San Diego
• Visit of the EDF Renewable Energy plant in San Diego
• Meeting with the San Diego Regional Economic Development Corporation

Tuesday, June 24^th:

• Signature of the Partnering agreement between Biocom and Eurobiomed
• Working lunch with the Maritime Alliance
• Meeting with Staff members of Congressman Scott Peters
• Meeting with organizations/development agencies from Baja California (Mexico)

Wednesday, June 25^th:

• BIO International Conference
• Life Sciences on Tap with SDREDC

All the pictures from this mission can be found at the following link.

FBB 42 – 2014 June 23rd-26th – PACA’s South BIO Alliance Delegation in San Diego

Officials of San Diego’s Biocom and Eurobiomed, an agency in southeastern Francce, sign an agreement to help biotech companies do business in each other’s regions. From left, Magda Marquet, founder of Althea Technologies and chair of Biocom; Jacquie Berthe, president of Eurobiomed and a scientific director of Sanofi-Aventis; and Joe Panetta, president and CEO of Biocom.

Formally establishing a relationship years in the making, San Diego’s life science trade group, Biocom has signed a economic development pact with a French governmental agency.

The deal between Biocom and Eurobiomed in southeastern France commits them to help their respective biomedical companies establish ties and do business in each other’s regions. Already, one French biotech company, Neuroservice, has joined Biocom, said Stéphane Richard, president and founder of French BioBeach, a San Diego Franco-American biotech networking group. Another company, Roowin, is in the process of joining.

Biocom and Eurobiomed officials signed the deal Tuesday morning in the French pavilion at the Biotechnology Industry Organization’s 2014 annual convention, held this year at the San Diego Convention Center. About 15,000 people are expected to attend through Thursday from 47 states and 65 countries. BIO 2014 is the world’s biggest biotech convention. It was previously held in San Diego, itself a top global biotech center, in 2001 and 2008.

Eurobiomed promotes biomedical economic development in the regions of Provence-Alpes-Côte d’Azur and Languedoc Roussillon. The territory includes the cities of Marseille, Nice and Montpellier on the Mediterranean coast. With four major university hospitals the area provides a strong health care infrastructure to complement research, said Jacquie Berthe, president of Eurobiomed.

“For American companies who want to develop their new drugs in Europe, it’s a good way to start clinical development,” Berthe said. “We’ve worked with Biocom for the past two years. Last year, for example, we had eight American companies go to the south of France, Marseille and Nice. This year, we have 12 companies from Eurobiomed attending BIO.”

“What we expect with the agreement with Biocom is to help American companies go to the south of France to find partners and to find financing, and to advance all their clinical trials and regulatory affairs.” Berthe said. “And we expect the same thing for French companies in California.”

Other aspects of the collaboration include training on how to meet European and U.S. regulations, saving money through combined purchasing agreements, and scientific exchanges.

Eurobiomed has more than 400 companies as members, including such major companies as Sanofi-Aventis, where Berthe is the scientific director of Sanofi’s center in Montpellier.

Stephane Richard of French BioBeach and Joe Panetta of Biocom speak at the signing of the Biocom/Eurobiomed partnership

This fall, Biocom will return to France, Joe Panetta, Biocom’s president and CEO, said at the signing ceremony.

Last year’s visit was arranged by French BioBeach, with help from Eurobiomed, Team Côte d’Azur, Provence Promotion and the regional economic development agency, MDER. Panetta wrote about the delegation’s trip to France last year in U-T San Diego.

French biotech initiatives toward San Diego combine private-sector businesses and groups with support from French governmental agencies. French BioBeach was founded in 2006 by Richard in partnership with the French Embassy in Washington, D.C.  In 2010, Richard, then with the French biological software company Medit SA, helped form a partnership between that company and the Sanford-Burnham Medical research Institute to improve drug-design by finding promising proteins for future development.

Eurobiomed itself is sponsored by the French regional governments, with about 60 percent of its funding coming from government sources, Berthe said. In contrast, Biocom is a wholly private entity. In addition, Eurobiomed helps with basic research, while Biocom does not.

Just to the north of Eurobiomed territory, the business development group Lyonbiopole also sent a delegation to the BIO convention. The group represents a biomedical cluster in and around the city of Lyon. Lyonbiopole’s Florence Agostino-Etchetto attended the Eurobiomed signing.

Lyonbiopole is also interested in building collaborations, including academic relationships, Agostino-Echetto said. The region is one of seven recognized biotechnology clusters in France. The region is known for its work on vaccines and therapies for infectious diseases and cancer.

“In California and in San Diego, there are a lot of organizations and companies in biotechnology we can collaborate with,” she said. “We hope our companies can find some good partners in San Diego.”

Lyonbiopole can help finance innovative projects and recruit people for them, she said.

Source: Union Tribune San Diego, http://www.utsandiego.com/news/2014/Jun/24/biocom-eurobiomed-france/2/?#article-copy

Acquisition Provides Opportunity to Accelerate Development of Selective Estrogen Receptor Degrader (SERD) Platform for the Treatment of Hormone Dependent Breast Cancer

July 1, 2014 San Diego, CA

Seragon Pharmaceuticals Inc., a leader in developing drugs for hormone dependent cancers, today announced a definitive agreement with Genentech, a member of the Roche Group, (SIX: RO, ROG; OTCQX: RHHBY) whereby Seragon will be acquired for $725 million in cash up front along with $1.0 billion in contingent development milestone payments that could bring the total transaction value to $1.725 billion.  The acquisition includes Seragon’s entire SERD program, including its most advanced compound, ARN-810, a next generation SERD that is currently being evaluated in a Phase I trial in patients with estrogen receptor positive (ER+) metastatic breast cancer.

Seragon, founded in August 2013, is an independent venture backed biotech company based in San Diego that was spun out of Aragon Pharmaceuticals, following its acquisition by Johnson & Johnson.  Following the spin out, Seragon retained many members of the management and R&D team, including Richard A. Heyman, Ph.D., Chief Executive Officer and co-founder of Aragon and Seragon Pharmaceuticals.  The Seragon team focused its attention to develop game changing therapies targeting ER+ breast cancer and other estrogen driven cancers including endometrial and ovarian cancers.

“This acquisition represents an ideal transition between biotech and pharma and may provide an optimal outcome for the SERD program and the breast cancer patient community.  The Seragon team has been committed to bringing new therapies to cancer patients and we are excited to have Genentech carry forward these programs.  Genentech has repeatedly demonstrated its leadership position the oncology field, and their development and commercial capabilities in the breast cancer area are unparalleled,” said Rich Heyman.

In the US alone, there are approximately 229,000 new breast cancer diagnoses and 40,000 deaths/year related to breast cancer.  The vast majority of these cancers are dependent on estrogen signaling and women with ER+ breast cancer are treated with 1st generation anti-hormonal therapies such as tamoxifen or the aromatase inhibitors. These therapies are initially effective, but many patients experience disease progression due to acquired resistance.  Seragon’s SERDs are next generation therapies that have a dual mechanism of action in that they both bind to the estrogen receptor to antagonize hormone action, and they promote receptor degradation.  These SERDs are initially being developed for the treatment of women with late-stage, progressive ER+ metastatic breast cancer, but they also have potential in treating patients with early-stage breast cancer.  Furthermore they also may offer an opportunity to be the cornerstone for future combination therapies.

“I would like to sincerely acknowledge Rich and the entire Seragon team for their commitment and dedication in advancing the ground breaking science behind both Seragon and Aragon.  In just five years since the founding of Aragon, in The Column Group’s offices, this team has advanced multiple compounds from an early idea to a clinical development program targeting hormone dependent cancers.   I would also like to thank Dr. Charles Sawyers for his foundational work helping to elucidate the molecular determinants of resistance for hormone dependent prostate cancer.  This is an ideal path, which will hopefully translate to improving the lives of patients,” said Peter Svennilson, Founder and Managing Partner of The Column Group and Chairman of both Seragon and former Chairman of Aragon.

The closing of the transaction is subject to customary closing conditions, including clearance under the Hart-Scott-Rodino Antitrust Improvements Act. The transaction is expected to close in the third quarter of 2014.

Wilson Sonsini Goodrich & Rosati served as legal advisor to Seragon Pharmaceuticals in this transaction.

About Seragon Pharmaceuticals

Seragon Pharmaceuticals is focused on the development of small-molecule drugs for the treatment of estrogen receptor dependent breast cancer. Seragon Pharmaceuticals’ orally active selective estrogen receptor degraders (SERDs) represent a potential new treatment for progressive metastatic breast cancer that may circumvent the problem of resistance to anti-hormonal therapies. The company’s lead SERD compound, ARN-810, is currently being evaluated in a Phase I clinical trial in breast cancer patients who have failed first generation anti-hormonal therapies such as tamoxifen and aromatase inhibitors.  In addition to endocrine-resistant breast cancer, SERD agents also have potential to treat other estrogen dependent cancers such as endometrial and ovarian cancers. Seragon is a privately held company founded in 2013 and headquartered in San Diego, California.  Seragon was financed by legacy Aragon investors including, The Column Group, OrbiMed Advisors, Aisling Capital, TopSpin and venBio.

For further information, please contact: Trisha Millican SVP of Finance & Chief Accounting Officer Seragon Pharmaceuticals (858) 369-7638

Source: Seragon Pharmaceuticals, http://seragonpharm.com/news/press-release-070214.htm

In the latest of our series to help the Scottish business community, Gareth Magee gives an insight into how to do business in France.

Population: approx. 67 million

Currency: Euro

Capital city: Paris

GDP: approx. US$2.6 trillion

Our close neighbour, France, boasts the fifth largest economy in the world, just ahead of the UK, which sits at number six. A mere few billion separates us, as well as the channel, and perhaps this is why relations between the UK and France go back a long way and continue, albeit more successfully, today.

Scientific Innovation in the Age of Experience

Chris Viehbacher, Chief Executive Officer of Sanofi, poses for the media before the company’s 2012 annual results presentation in Paris February 7, 2013.

Source (Reuters) – Sanofi SA is looking to sell a portfolio of older drugs that could fetch $7-8 billion, according to people familiar with the matter, yet another example of drugmakers trying to shed non-core assets and focus on high-growth areas.

The French pharmaceutical firm has hired financial advisers Evercore Partners Inc to help it with a deal and has contacted potential buyers in the past few months, the people said, asking not to be named because the matter is private.

The drugs for sale include treatments for high blood pressure and cardio-metabolic diseases and account for roughly $3.7 billion in combined annual revenue, one of the people said.

The portfolio could fetch up to two times that amount, the person added.

Shares in Sanofi rose 1.5 percent in early trade on Wednesday following the news.

Generic drugmakers and specialty pharmaceutical companies are seen as logical buyers for the portfolio, said the people familiar with the matter.

A spokesman for Sanofi said: “We do not comment on market rumors.” Evercore also declined to comment.

Drug companies are increasingly looking to shed smaller divisions they view as non-core so they can better focus on their mainstay products. They have also shown willingness to consider large asset swaps with rivals to exit weaker businesses and reinforce core areas where they are already top players.

Novartis AG last week announced a major revamp in which it traded more than $20 billion worth of assets with GlaxoSmithKline Plc and agreed to sell its animal health arm to Eli Lilly and Co.

Merck & Co Inc is also in the final stages of selling its consumer health unit for close to $14 billion, Reuters reported last week, as its market share in the sector is seen as sub-scale compared with those of market leaders.

The Novartis deal, in particular, is seen as a template for others in the pharmaceuticals industry to follow and it could also apply to other industries, such as consumer goods.

Sanofi has an extensive line-up of older products that could be carved out, following similar moves now under way at Pfizer Inc and GSK to place older products in separate divisions.

Pfizer announced last year it planned to separate its business into three units – innovative pharmaceuticals; vaccines, oncology and consumer health; and established products – and the U.S. group has not ruled out a full breakup.

GSK is starting out down a similar path and will announce the first separate results for its established products business when it reports quarterly results later on Wednesday.

Sanofi Chief Executive Chris Viehbacher said on Tuesday he did not plan to embark on large-scale deals, despite a current merger frenzy in the healthcare sector, but would continue with a strategy of smaller transactions and bolt-on acquisitions.

(Reporting by Ben Hirschler; Editing by Steve Orlofsky, Bernard Orr and Mark Potter)

Drug candidate blocks production of disease-causing neurotoxins in mouse models.

A team of scientists from the University of California, San Diego School of Medicine, the Medical University of South Carolina and San Diego-based American Life Science Pharmaceuticals, Inc., report that cathepsin B gene knockout or its reduction by an enzyme inhibitor blocks creation of key neurotoxic pGlu-Aβ peptides linked to Alzheimer’s disease (AD). Moreover, the candidate inhibitor drug has been shown to be safe in humans.

The findings, based on AD mouse models and published online in the Journal of Alzheimer’s Disease, support continued development of cysteine protease inhibitors as a new drug target class for AD. “No other therapeutic program is investigating cysteine protease inhibitors for treating AD,” said collaborator Vivian Hook, PhD, professor in the UC San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences and in the UC San Diego School of Medicine.

Current AD drugs treat some symptoms of the devastating neurological disorder, but none actually slow its progress, prevent or cure it. No new AD drug has been approved in more than a decade.

The researchers focused on cathepsin B production of N-truncated pGlu-Aβ, a peptide or short chain of amino acids, and the blockade of cathepsin B by E64d, a compound shown to inhibit cysteine proteases, a type of enzyme. AD is characterized by accumulation of a variety of Aβ peptides as oligomers and amyloid plaques in the brain, factors involved in neuronal loss and memory deficits over time. These neurotoxic Aβ peptides are created when enzymes cleave a large protein called amyloid precursor protein (APP) into smaller Aβ peptides of varying toxicity. N-truncated pGlu-Aβ has been shown to be among the most neurotoxic of multiple forms of Aβ peptides.

Much AD research has focused on the APP-cutting enzyme BACE1 β-secretase, but its role in producing pGlu-Aβ was unknown. Cathepsin B is an alternative -secretase which cleaves the wild-type β-secretase site of APP, which is expressed in the major sporadic and many familial forms of AD. Hook and colleagues looked at what happened after gene knockout of BACE1 or cathepsin B. They found that cathepsin B, but not BACE1, produced the highly toxic pGlu-Aβ.

Perhaps most interestingly, the scientists found that E64d, an enzyme inhibitor of cathepsin B, reduced production of pGlu-Aβ and other AD-associated Aβ peptides. Key was the finding that E64d and cathepsin B gene knock out resulted in improved memory deficits in a mouse model of AD.

“This is an exciting finding,” said Hook. “It addresses a new target – cathepsin B – and an effective, safe small molecule, E64d, to reduce the pGlu-Aβ that initiates development of the disease’s neurotoxicity. No other work in the field has addressed protease inhibition for reducing pGlu-Aβ of AD.”

Hook noted that E64d has already been shown to be safe in clinical trials of patients with muscular dystrophy and would, therefore, likely prove safe for treating AD as well. She hopes to launch Phase 1 human clinical trials in the near future with a modified version of the drug candidate.

Co-authors include Gregory Hook, American Life Science Pharmaceuticals, Inc.; Jin Yu and Mark Kindy, Medical University of South Carolina; and Thomas Toneff, UCSD Skaggs School of Pharmacy and Pharmaceutical Sciences.

Funding for this research came, in part, from the National Institutes of Health (grants R44AG032784, R01ES016774-02 and R21AG0428), a Veteran’s Affairs Merit Review grant, and an Alzheimer’s Association award.

Disclosure Vivian Hook is chair of American Life Science Pharmaceuticals’ scientific advisory board and holds equity in the company.

Media contact: Scott LaFee, 619-543-6163, slafee@ucsd.edu

Source: UCSD Health System, http://health.ucsd.edu/news/releases/Pages/2014-03-17-17-new-therapeutic-alzheimers-target.aspx

MabThera SC offers a faster administration time for patients in Europe while potentially saving valuable time for health systems

SAN DIEGO, March 28, 2014 /PRNewswire/ — Halozyme Therapeutics, Inc.(NASDAQ: HALO) announced today that the European Commission (EC) has approved Roche’s new subcutaneous (SC) formulation of MabThera^® (rituximab) for the treatment of patients with follicular lymphoma and diffuse large B-cell lymphoma. Following the approval of Herceptin SC in September 2013, this is the second European approval for a novel subcutaneous formulation of one of Roche’soncology products using Halozyme’s patented Enhanze™ (recombinant human hyaluronidase) technology.

“Today’s approval in the EU offers another treatment option for patients with common forms of non-Hodgkin lymphoma and is yet another validating milestone for our proprietary technology,” said Dr. Helen Torley, President and Chief Executive Officer. “With an administration time of approximately five minutes compared to the approximately 2.5 hour infusion time for intravenous MabThera, this innovative formulation could potentially save time for patients, physicians and other health care providers in Europe.”

The European approval was primarily based on data from the pivotal SABRINA study, which was recently published in the Lancet Oncology[i].

Roche has stated that they expect to begin launching MabThera SC in a number of European markets throughout 2014.

About non-Hodgkin lymphoma
There are two main types of lymphoma: Hodgkin lymphoma and non-Hodgkin lymphoma (NHL). NHL represents approximately 85% of all lymphoma diagnosed[ii] and was responsible for approximately 200,000 annual deaths worldwide in 2012[iii].

Lymphomas are a cancer of the lymphatic system (composed of lymph vessels, lymph nodes and organs) which helps to keep the bodily fluid levels balanced and to defend the body against invasion by disease. Lymphoma develops when white blood cells (usually B-lymphocytes) in the lymph fluid become cancerous and begin to multiply and collect in the lymph nodes or lymphatic tissues such as the spleen. Some of these cells are released into the bloodstream and spread around the body, interfering with the body’s production of healthy blood cells.

Halozyme-Roche Collaboration
In December 2006, Halozyme entered into an agreement with Roche to apply Halozyme’s patented Enhanze™ technology (recombinant human hyaluronidase or rHuPH20) to Roche’s biological therapeutic compounds. To date, Roche has elected to explore the use of rHuPH20 for up to a total of five exclusive targets, and Rocheretains the option to apply rHuPH20 to three additional targets through the payment of annual license maintenance fees. Subject to the successful achievement of clinical, regulatory, and sales events, Roche will pay Halozyme additional milestones as well as royalties on product sales for Herceptin SC, MabThera SC and any other product candidates which would be successfully developed and commercialized under the agreement.

About Halozyme
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company’s research focuses primarily on a family of human enzymes, known as hyaluronidases, which increase the dispersion and absorption of biologics, drugs and fluids. Halozyme’s pipeline addresses therapeutic areas, including oncology, diabetes and dermatology that have significant unmet medical need today. The Company markets Hylenex^® recombinant (hyaluronidase human injection) and has partnerships with Roche, Pfizer and Baxter. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at www.halozyme.com and follow us on Twitter@HALOTherapeutic.

Safe Harbor Statement
This release includes forward-looking statements such as the potential benefits of MabThera SC to patients, physicians and the healthcare system, and the possible receipt by Halozyme of future milestones and royalties under the Halozyme-Roche collaboration agreement. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: the approval of product candidates under the Halozyme-Roche collaboration by applicable regulatory authorities; satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; issues encountered in the sale of MabThera SC and other product candidates under the Halozyme-Roche collaboration including the countries where the product is approved, approval timelines, the rate of conversion of IV formulation users to SC users, pricing and other commercial factors; unexpected adverse events; changes in laws and regulations; competitive conditions; and other risks identified in Halozyme’s Annual Report on Form 10-K filed with the Securities and Exchange Commission onFebruary 28, 2014. Halozyme does not undertake to update its forward-looking statements.

References:

 

---

 

[i] Davies, A. et al. (2014) Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study The Lancet Oncology, Early Online Publication, 10 February 2014
doi:10.1016/S1470-2045(14)70005-1
[ii] Globocan (2012) Table by cancers. Worldwide incidence of cancers in males and females.
http://globocan.iarc.fr/ (URL accessed 3.03.14).
[iii] Globocan (2012) Cancer Incidence and Mortality Worldwide. World, non-Hodgkin lymphoma, 2010. (URL accessed 18.09.13).http://globocan.iarc.fr/Pages/fact_sheets_population.aspx
(URL accessed 03.03.14).

Investor Contact:
Schond Greenway
Halozyme Therapeutics
858-704-8352
ir@halozyme.com

Source: Halozyme Therapeutics, Inc., http://www.halozyme.com/Investors/News-Releases/News-Release-Details/2014/Halozyme-Announces-Roche-Marketing-Authorization-For-MabThera-SC-For-Patients-With-Common-Forms-Of-Non-Hodgkin-Lymphoma-In-European-Union/default.aspx